Abstract
Objective To investigate the efficacy and safety of recombinant human interferon alpha (rhIFN-α) nasal drops in healthy medical staff to prevent coronavirus disease 2019 (COVID-19).
Methods A prospective, open-label study was conducted in January 21, 2020at Taihe Hospital in Shiyan City, Hubei Province. Totally, 2944 medical staff members were recruited and allocated into low-risk group or high-risk group according to whether they were directly exposed to COVID-19 patients. Participants in the low-risk group received rhIFN-α nasal drops (2–3 drops/nostril/time, 4 times/day) for 28 days with first-level protection; those in the high-risk group received identical rhIFN-α nasal drops combined with thymosin-α1 (1.6 mg, hypodermic injection, once a week) along with secondary-level or third-level protection. The primary outcome was new-onset COVID-19 over 28 days. The secondary outcome was new-onset fever or respiratory symptoms but with negative pulmonary images. The results were compared with new-onset COVID-19 in medical staff in Hubei Province (including Wuhan) during the same period. Adverse reactions to interferon nasal drops were also observed.
Results Among the 2944 subjects in our study, 2415 were included in the low-risk group, including 997 doctors and 1418 nurses with average ages of 37.38 and 33.56 years, respectively; 529 were included in the high-risk group, including 122 doctors and 407 nurses with average ages of 35.24 and 32.16 years, respectively. The 28-day incidence of COVID-19 was zero in both the high and low-risk groups. The 28-day incidence of new-onset clinical symptoms with negative images for pneumonia was also zero in both the high and low-risk groups. As control, a total of 2035 medical personnel with confirmed COVID-19 from the same area (Hubei Province) was observed between January 21 to February 23, 2020. No serious adverse events were observed in our trial during the intervention period.
Conclusion In this investigator-initiated open-label study, we observed that rhIFN-α nasal drops may effectively prevent COVID-19 in medical staff, as an enhancement protection on the basis of standard physical isolation. Our results also indicate that rhIFN-α nasal drops have potential promise for protecting susceptible healthy people during the coronavirus pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04320238
Funding Statement
This work was supported by the National Science and Technology Major Project (Grant No. 2018ZX10723203 and 2018ZX10302206).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant support: This work was supported by the National Science and Technology Major Project (Grant No. 2018ZX10723203 and 2018ZX10302206).
Disclosures: The authors declare that they have no conflict of interest.
Data Availability
The data used to support the findings of this study are included within the article.
